Literature DB >> 696350

Influence of intravenously administered catecholamines on cerebral oxygen consumption and blood flow in the rat.

L Berntman, N Dahlgren, B K Siesjö.   

Abstract

In order to study effects of catecholamines on cerebral oxygen consumption (CMRo2) and blood flow (CBF), rats maintained on 75% N2O and 25% O2 were infused i.v. with noradrenaline (2, 5, or 8 microgram.kg-1.min-1) or adrenaline (2 or 8 microgram.kg-1.min-1) for 10 min before CBF and CMRo2 were measured. In about 50% of animals infused with 2--8 microgram.kg-1.min-1 of noradrenaline, CMRo2 (and CBF) rose. However, there was no dose-dependent response, and CMRo2 did not exceed 150% of control. The effects of noradrenaline in a dose of 5 microgram.kg-1.min-1 on CMRo2 and CBF were blocked by propranolol (2.5 mg.kg-1). In animals infused with adrenaline (8 microgram.kg-1.min-1) CMRo2 was doubled and, in many, CBF rose 4- to 6-fold. It is concluded that, when given in sufficient amounts, catecholamines have pronounced effects on cerebral metabolism and blood flow, the effects of adrenaline on CMRo2 and CBF resembling those observed in status epilepticus.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 696350     DOI: 10.1111/j.1748-1716.1978.tb06255.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  3 in total

1.  A comparison of the cerebral pressure-flow relationship for halothane and isoflurane at haemodynamically equivalent end-tidal concentrations in the rabbit.

Authors:  W A Mutch; P M Patel; T S Ruta
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

2.  The effects of intravenous norepinephrine on the local coupling between glucose utilization and blood flow in the rat brain.

Authors:  W Kuschinsky; S Suda; R Bünger; S Yaffe; L Sokoloff
Journal:  Pflugers Arch       Date:  1983-07       Impact factor: 3.657

3.  Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis.

Authors:  David Di Giantomasso; Clive N May; Rinaldo Bellomo
Journal:  Intensive Care Med       Date:  2003-04-16       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.